Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q4VNC1

UPID:
AT134_HUMAN

ALTERNATIVE NAMES:
P5-ATPase isoform 4

ALTERNATIVE UPACC:
Q4VNC1; B7WPC7; Q6UY23; Q8N1Q9; Q9H043

BACKGROUND:
Probable cation-transporting ATPase 13A4, alternatively named P5-ATPase isoform 4, is integral to the regulation of ion concentrations within cells. This protein's activity is essential for the proper functioning of cellular mechanisms, highlighting its importance in biological systems.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Probable cation-transporting ATPase 13A4 offers a promising avenue for the development of novel therapeutic approaches. The protein's role in maintaining ion homeostasis makes it a potential target for treating disorders associated with ion imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.